Biomarker: F093-IgE Chocolate/Cacao

Overview

F093-IgE Chocolate/Cacao measures serum allergen-specific immunoglobulin E (sIgE) antibodies directed against chocolate or cacao proteins. IgE can bind to receptors on mast cells and basophils, contributing to immediate allergic reactions after exposure to a sensitizing allergen. A detectable or elevated result indicates sensitization, but does not by itself prove clinical allergy or predict reaction severity. The test is clinically useful as part of an allergy-focused evaluation, particularly when symptoms occur soon after consuming chocolate or cacao, but results should be interpreted with the clinical history and, when necessary, a supervised oral food challenge.

Clinical Use Cases

Evaluating suspected IgE-mediated chocolate or cacao allergy in patients with compatible immediate symptoms.
Supporting assessment of reactions such as hives, swelling, vomiting, wheezing, or anaphylaxis after chocolate or cacao exposure.
Identifying sensitization to cacao as part of a broader food-allergy evaluation.
Helping distinguish possible cacao sensitization from reactions caused by other ingredients commonly present in chocolate products, such as milk, peanut, tree nuts, or other additives.
Supporting decisions about further evaluation, dietary avoidance, or a medically supervised oral food challenge.
Monitoring sensitization over time when clinically indicated, although changes in sIgE do not independently establish tolerance or reaction severity.

Specimen Types

Venous blood serum, typically collected in a serum gel or red-top tube.
Plasma is not generally the standard specimen for this specific serum assay.

Measurement Methods

In-vitro allergen-specific IgE immunoassay using cacao or cocoa allergen extract attached to a solid-phase platform.
Fluorescence-based immunoassay methods, such as an ImmunoCAP-type assay, in which patient IgE binds to immobilized allergen and is detected with enzyme-labeled anti-human IgE.
Skin-prick testing with chocolate or cacao extract may be used as a complementary in-vivo assessment, but it is not the same as the F093 serum biomarker.
An oral food challenge may be used to determine clinical reactivity when the history and allergy testing are inconclusive; it is performed under medical supervision.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergy blood test.
Tell the healthcare professional about all medications. Antihistamines may affect skin-prick testing, but they generally do not prevent blood-based sIgE measurement. Do not stop medication unless instructed by a healthcare professional.
Results should be interpreted with the timing, reproducibility, and nature of symptoms after chocolate or cacao exposure.
A positive result indicates sensitization and does not confirm clinical allergy or predict how severe a future reaction will be.
False-positive or clinically irrelevant results may occur, particularly when testing is performed without a compatible clinical history.
Total IgE level, age, atopic dermatitis, pollen sensitization, and other allergic conditions may influence interpretation of food sIgE results.
Chocolate products may contain multiple potential allergens. A reaction to a product does not establish that cacao itself is the causative allergen.
Blood samples are typically collected as serum and should be handled according to the performing laboratory’s specimen requirements.